Literature DB >> 14616487

Management of the primary cutaneous lymphomas.

H Miles Prince1, Christopher McCormack, Gail Ryan, Rod O'Keefe, John F Seymour, Chris Baker.   

Abstract

Cutaneous lymphomas are rare and, although some are a manifestation of systemic lymphoma, the majority arise primarily from the skin. These primary cutaneous lymphomas comprise both T- and B-cell subtypes and represent a wide spectrum of disorders, which at times can be difficult to diagnose and classify. Classical therapeutic strategies include topical corticosteroids, phototherapy, radiotherapy, retinoids, extracorporeal photopheresis, topical chemotherapy, systemic chemotherapy and biological response modifiers. Newer therapies include the synthetic retinoid bexarotene, the immunotoxin conjugate denileukin diftitox, interleukin-12 and monoclonal antibodies such as alemtuzumab and rituximab.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616487     DOI: 10.1046/j.1440-0960.2003..x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  2 in total

1.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Authors:  L Marquard; L M Gjerdrum; Ib J Christensen; P B Jensen; M Sehested; E Ralfkiaer
Journal:  Histopathology       Date:  2008-09       Impact factor: 5.087

2.  "Interaction between bcl2 and jun B in primary cutaneous lymphoma: a gene ontology approach": a comment on the new approach in dermatology.

Authors:  Viroj Wiwanitkit
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.